Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Extension Study to Obtain Long-term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001

NCT00758225 is registered in ClinicalTrials.gov with Santhera Pharmaceuticals as lead sponsor.

NCT NCT00758225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00758225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Extension Study to Obtain Long-term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001
Lead sponsor
Santhera Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2008
Completion date
January 31, 2011
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy